within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD02_CoagulationFactorViii;

model CoagulationFactorViii
  extends Pharmacolibrary.Drugs.ATC.B.B02BD02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B02BD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Coagulation factor VIII is a multifunctional glycoprotein playing a crucial role in the blood clotting cascade. It is primarily used for the treatment and prophylaxis of bleeding in individuals with hemophilia A, a genetic deficiency of factor VIII. Factor VIII is approved as a replacement therapy and is administered as either plasma-derived or recombinant concentrate products.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with severe hemophilia A who received a single intravenous dose of recombinant factor VIII concentrate.</p><h4>References</h4><ol><li><p>Hermans, C, &amp; Pierce, GF (2024). Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. <i>Journal of thrombosis and haemostasis : JTH</i> 22(7) 1844–1846. DOI:<a href=\"https://doi.org/10.1016/j.jtha.2024.04.010\">10.1016/j.jtha.2024.04.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38679336/\">https://pubmed.ncbi.nlm.nih.gov/38679336</a></p></li><li><p>Gaitonde, P, et al., &amp; Balu-Iyer, SV (2015). Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 66 157–162. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2014.10.010\">10.1016/j.ejps.2014.10.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25459532/\">https://pubmed.ncbi.nlm.nih.gov/25459532</a></p></li><li><p>Nestorov, I, et al., &amp; Rogge, M (2015). Population pharmacokinetics of recombinant factor VIII Fc fusion protein. <i>Clinical pharmacology in drug development</i> 4(3) 163–174. DOI:<a href=\"https://doi.org/10.1002/cpdd.167\">10.1002/cpdd.167</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27140796/\">https://pubmed.ncbi.nlm.nih.gov/27140796</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CoagulationFactorViii;
